Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCCLG-M5: CLAG and Sorafenib for Pediatric Acute Monocytic Leukemia
NCT05313958Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Dec 2021
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of cladribine in acute monocytic leukemia (AML-M5), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Overall Survival at 3 years. Started Dec 2021; status: recruiting.
02
Drugs
cladribine
03
Conditions
acute monocytic leukemia (AML-M5)
Beyond the preview
Go deeper on NCT05313958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05313958.